Abstract
Background The International Immunoglobulin A nephropathy (IgAN) risk prediction assesses the risk of kidney failure in patients with IgAN. The performance of this risk prediction tool has not been studied in American Indians and Hispanics. We conducted a single-center study to assess the equation performance in this population.
Methods We calculated the 5-year risk of developing kidney failure with the IgAN risk prediction equation without race and assessed the equation performance using the metrics of calibration, discrimination, and overall prediction error.
Results Thirty-four patients were included, most of whom identified as of Hispanic race/ethnicity (44.1%), or as American Indians (26.5%). At biopsy, the median (IQR) age, serum creatinine, and spot urine protein to creatinine ratio were 38 years (27-45), 2.15 mg/dl (1.51-3.04), and 2.7 g/g (1.5-5.8), respectively. The equation identified patients at high risk of developing kidney failure early with a concordance statistic of 0.79 (95% CI 0.68 – 0.89). The agreement between observed and predicted outcomes at 5 years was marginal, with over-estimation of risk for patients with low observed risk and vice versa. Overall prediction error was suboptimal in this cohort [index of prediction accuracy 0.34 (0.03 – 0.51)].
Conclusions The International IgAN risk prediction equation without race accurately identified patients at elevated risk of developing kidney failure. At 5 years, the agreement between the observed and predicted outcomes was sub-optimal, possibly due to advanced kidney disease in this cohort. A diverse development population may improve the risk prediction.
Competing Interest Statement
Saeed Kamran Shaffi: Advisory board: Novartis Christos Argyropoulos: Consultant Agreements: Bayer, Baxter, Otsuka, Quanta
Funding Statement
Saeed K Shaffi: The University of New Mexico Kidney biopsy registry was established by funding from the Dialysis Clinic, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of New Mexico Health Sciences Center Human Research Review Committee waived the requirements for informed consent and HIPAA authorization addendum. The request was approved on 9/21/2016 and is valid till 1/5/2024.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
Restrictions to the data apply; as per the University of New Mexico Institutional Review Board, an IRB modification with a data sharing agreement is required to provide data but can be arranged upon request.
